Ken Griffin Supernus Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 15,000 shares of SUPN stock, worth $541,800. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,000

Previous 10,600 41.51%

Holding current value

$541,800

Previous $283,000 65.02%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$25.77 - $35.16 $996,783 - $1.36 Million	-38,680 Reduced 27.06%	104,252 $3.25 Million
Q2 2024 Aug 14, 2024	BUY	$25.99 - $33.85 $1.45 Million - $1.88 Million	55,638 Added 63.74%	142,932 $3.82 Million
Q1 2024 May 15, 2024	SELL	$27.11 - $35.17 $3.33 Million - $4.32 Million	-122,827 Reduced 58.46%	87,294 $2.98 Million
Q4 2023 Feb 14, 2024	SELL	$22.72 - $29.68 $3.76 Million - $4.92 Million	-165,705 Reduced 44.09%	210,121 $6.08 Million
Q3 2023 Nov 14, 2023	BUY	$27.57 - $32.91 $7.91 Million - $9.44 Million	286,839 Added 322.34%	375,826 $10.4 Million
Q2 2023 Aug 14, 2023	SELL	$29.91 - $38.73 $453,644 - $587,417	-15,167 Reduced 14.56%	88,987 $2.67 Million
Q1 2023 May 15, 2023	SELL	$34.93 - $42.03 $10.1 Million - $12.2 Million	-289,681 Reduced 73.55%	104,154 $3.77 Million
Q4 2022 Feb 14, 2023	BUY	$31.09 - $37.88 $2.62 Million - $3.19 Million	84,144 Added 27.17%	393,835 $14 Million
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $6.24 Million - $7.68 Million	216,771 Added 233.29%	309,691 $10.5 Million
Q2 2022 Aug 15, 2022	SELL	$25.33 - $34.25 $337,927 - $456,929	-13,341 Reduced 12.55%	92,920 $2.69 Million
Q1 2022 May 16, 2022	SELL	$28.51 - $32.9 $24,347 - $28,096	-854 Reduced 0.8%	106,261 $3.43 Million
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $2.42 Million - $3.14 Million	91,880 Added 603.09%	107,115 $3.12 Million
Q3 2021 Nov 15, 2021	SELL	$23.54 - $31.39 $9.16 Million - $12.2 Million	-389,288 Reduced 96.23%	15,235 $406,000
Q2 2021 Aug 16, 2021	BUY	$26.72 - $33.19 $9.42 Million - $11.7 Million	352,367 Added 675.6%	404,523 $12.5 Million
Q1 2021 May 17, 2021	BUY	$24.15 - $31.45 $895,482 - $1.17 Million	37,080 Added 245.95%	52,156 $1.37 Million
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $12.4 Million - $18 Million	-698,164 Reduced 97.89%	15,076 $379,000
Q1 2020 May 15, 2020	BUY	$14.45 - $24.69 $6.24 Million - $10.7 Million	432,084 Added 153.68%	713,240 $12.8 Million
Q4 2019 Feb 14, 2020	BUY	$19.93 - $29.13 $1.04 Million - $1.52 Million	52,236 Added 22.82%	281,156 $6.67 Million
Q3 2019 Nov 14, 2019	BUY	$25.47 - $33.37 $2.4 Million - $3.15 Million	94,365 Added 70.13%	228,920 $6.29 Million
Q2 2019 Aug 14, 2019	SELL	$29.96 - $38.87 $362,006 - $469,666	-12,083 Reduced 8.24%	134,555 $4.45 Million
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $2.35 Million - $3.01 Million	71,646 Added 95.54%	146,638 $0
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $898,307 - $1.44 Million	29,128 Added 63.51%	74,992 $2.49 Million
Q3 2018 Nov 13, 2018	SELL	$42.7 - $56.55 $1.26 Million - $1.67 Million	-29,610 Reduced 39.23%	45,864 $0
Q2 2018 Aug 10, 2018	SELL	$44.1 - $59.85 $6.09 Million - $8.27 Million	-138,170 Reduced 64.67%	75,474 $0
Q1 2018 May 11, 2018	BUY	$37.15 - $46.9 $7.47 Million - $9.44 Million	201,204 Added 1617.4%	213,644 $9.79 Million
Q4 2017 Feb 09, 2018	SELL	$36.4 - $42.6 $2.24 Million - $2.62 Million	-61,463 Reduced 83.17%	12,440 $496,000
Q3 2017 Nov 09, 2017	BUY	$36.75 - $49.65 $2.72 Million - $3.67 Million	73,903	73,903 $2.96 Million

Others Institutions Holding SUPN

# of Institutions

282

Shares Held

60.9M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account